Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN-001 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Genome & Company
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
GEN-001 + pembrolizumab is an **investigational combination therapy** consisting of GEN-001, an orally-administered live biotherapeutic product (LBP) designed to modulate the gut microbiome to enhance the body's antitumor immune responses, and pembrolizumab, a monoclonal antibody immune checkpoint inhibitor targeting PD-1 developed by Merck (as Keytruda). GEN-001 is thought to enhance and broaden the response to immune checkpoint blockade by modulating the host immune microenvironment via the gut microbiota. The combination is being evaluated primarily for the treatment of advanced biliary tract cancer in patients who have failed prior standard therapies. GEN-001 is developed by Genome & Company, and pembrolizumab by Merck (MSD)[3][5].
- Brand names
- Keytruda
- Other names
- pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on GEN-001 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN-001 + pembrolizumab.